Compare Mimetogen Pharmaceuticals vs Prolexys Pharmaceuticals
Customers evaluate the quality of Mimetogen Pharmaceuticals's products using the following success metrics.
Overview
Mimetogen Pharmaceuticals is based in Canada
Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.
Prolexys Pharmaceuticals is 23 yrs old and is based in United States.
Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.
Demo Video
Leadership
Martin B. Wax (Chief Executive Officer)
David L Clark (Chief Executive Officer)
Funding
Investors
Medwell Capital, Inovia Capital
Friedli Corporate Finance and New Venturetec
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Mimetogen Pharmaceuticals has not claimed their profile.
Work for Mimetogen Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Mimetogen Pharmaceuticals?
Claim your profile now.
Information not available because Prolexys Pharmaceuticals has not claimed their profile.
Work for Prolexys Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Prolexys Pharmaceuticals?
Claim your profile now.